DexCom (NASDAQ:DXCM) Stock Price Target Raised at UBS Group

DexCom (NASDAQ:DXCM) had its target price increased by stock analysts at UBS Group from $102.00 to $107.00 in a research report issued on Friday, Benzinga reports. The firm currently has a “buy” rating on the medical device company’s stock. UBS Group‘s target price would suggest a potential upside of 30.03% from the stock’s previous close.

Several other brokerages also recently weighed in on DXCM. Royal Bank Of Canada restated an “outperform” rating and issued a $105.00 target price (up from $90.00) on shares of DexCom in a research note on Thursday, October 1st. Benchmark upped their price objective on shares of DexCom from $77.00 to $82.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Wall Street Zen upgraded DexCom from a “hold” rating to a “buy” rating in a research note on Sunday, September 6th. Citigroup restated a “buy” rating and set a $88.00 target price (up from $84.00) on shares of DexCom in a research note on Friday, July 31st. Finally, Stifel Nicolaus set a $95.00 price target on DexCom and gave the stock a “buy” rating in a research note on Friday, July 31st. Two analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $93.70.

DexCom Stock Performance

NASDAQ DXCM opened at $82.29 on Friday. The business’s 50-day simple moving average is $85.82 and its 200-day simple moving average is $74.65. The firm has a market capitalization of $30.69 billion, a P/E ratio of 32.27, a P/E/G ratio of 1.37 and a beta of 1.45. DexCom has a 1-year low of $54.11 and a 1-year high of $92.59. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.74 and a quick ratio of 1.40.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, October 29th. The medical device company reported $0.73 EPS for the quarter, beating analysts’ consensus estimates of $0.68 by $0.05. The business had revenue of $1.34 billion for the quarter, compared to the consensus estimate of $1.33 billion. DexCom had a net margin of 19.42% and a return on equity of 37.77%. The business’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same quarter last year, the firm posted $0.61 EPS. Equities analysts predict that DexCom will post 2.67 EPS for the current year.

Insider Buying and Selling at DexCom

In other news, EVP Sadie Stern sold 2,565 shares of the company’s stock in a transaction that occurred on Tuesday, October 27th. The stock was sold at an average price of $78.62, for a total transaction of $201,660.30. Following the completion of the transaction, the executive vice president directly owned 120,913 shares of the company’s stock, valued at approximately $9,506,180.06. This represents a 2.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nicholas Augustinos sold 6,539 shares of the company’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $84.04, for a total value of $549,537.56. Following the transaction, the director owned 29,293 shares of the company’s stock, valued at approximately $2,461,783.72. The trade was a 18.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 22,822 shares of company stock valued at $1,920,193 over the last three months. 0.28% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Mather Group LLC. grew its position in DexCom by 27.7% in the 3rd quarter. Mather Group LLC. now owns 563 shares of the medical device company’s stock worth $49,000 after purchasing an additional 122 shares during the last quarter. Fifth Third Wealth Advisors LLC raised its holdings in shares of DexCom by 2.8% during the third quarter. Fifth Third Wealth Advisors LLC now owns 5,510 shares of the medical device company’s stock valued at $475,000 after buying an additional 150 shares during the last quarter. Elevation Wealth Partners LLC boosted its position in shares of DexCom by 61.0% during the third quarter. Elevation Wealth Partners LLC now owns 401 shares of the medical device company’s stock worth $35,000 after buying an additional 152 shares during the period. MassMutual Private Wealth & Trust FSB grew its holdings in DexCom by 15.4% in the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 1,147 shares of the medical device company’s stock worth $77,000 after buying an additional 153 shares in the last quarter. Finally, Simplicity Wealth LLC grew its holdings in DexCom by 5.4% in the 3rd quarter. Simplicity Wealth LLC now owns 3,169 shares of the medical device company’s stock worth $273,000 after buying an additional 162 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

About DexCom

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its devices use a small wearable sensor to measure glucose levels in real time and transmit readings to compatible smartphones, receivers, smartwatches, and other connected devices, helping users monitor glucose trends and make informed decisions about their health.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 CGM systems, as well as Dexcom ONE and Dexcom ONE+ products offered in select markets.